Thu, October 3, 2024
[ 12:00 AM ] - WOPRAI
Tue, October 1, 2024
[ 12:00 AM ] - WOPRAI
Mon, September 23, 2024
[ 12:00 AM ] - WOPRAI
Mon, September 16, 2024
[ 12:00 AM ] - WOPRAI
Mon, September 9, 2024
[ 12:00 AM ] - WOPRAI
Fri, September 6, 2024
[ 12:00 AM ] - WOPRAI
Tue, August 6, 2024
Mon, July 29, 2024
Thu, June 20, 2024
Wed, June 5, 2024
Thu, May 9, 2024
Wed, April 24, 2024
Wed, April 3, 2024
Mon, January 8, 2024
Fri, September 22, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 22, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, August 8, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 1, 2023
[ 12:00 AM ] - WOPRAI
Mon, July 17, 2023
[ 12:00 AM ] - WOPRAI
Fri, July 14, 2023
[ 12:00 AM ] - WOPRAI
Thu, May 18, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 14, 2023
[ 12:00 AM ] - WOPRAI
Wed, November 2, 2022
[ 12:00 AM ] - WOPRAI
Tue, August 16, 2022
Pete Stavropoulos Reiterated (VERA) at Buy and Held Target at $107 on, Oct 3rd, 2024
Pete Stavropoulos of Cantor Fitzgerald, Reiterated "Vera Therapeutics, Inc." (VERA) at Buy and Held Target at $107 on, Oct 3rd, 2024.
Pete has made no other calls on VERA in the last 4 months.
There is 1 other peer that has a rating on VERA. Out of the 1 peers that are also analyzing VERA, 0 agree with Pete's Rating of Hold.
This is the rating of the analyst that currently disagrees with Pete
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $72 on, Tuesday, September 3rd, 2024
Contributing Sources